title: The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
abstract: BACKGROUND
  Determining the direct cost of providing medical care to patients with HIV/AIDS is important for both short-term and long-term decision-making and for appropriate resource allocation. We aimed to categorize and measure the direct costs of medical care provided to the entire HIV-positive population receiving care in southern Alberta between 1995 and 2001.
  
  
  METHODS
  We collected all patient-specific direct costs including the cost of pharmaceutical drugs (HIV and non-HIV drugs), outpatient care (including physician costs and laboratory testing), inpatient (in-hospital) care and home care (acute, long-term, palliative) from primary sources for all patients between April 1995 and April 2001. We determined cost per patient per month (PPPM) adjusted to 2001 Canadian dollars.
  
  
  RESULTS
  Since 1995, the direct cost of providing medical care to patients with HIV/AIDS has increased primarily as a result of increased antiretroviral drug costs both in absolute and in PPPM terms. Mean PPPM expenditures increased from 655 Canadian dollars in 1995/96, that is, before the use of highly active antiretroviral therapy (HAART), to 1036 Canadian dollars in 1997/98 when HAART was widely used. During the following 3 years, mean overall PPPM costs remained stable. Antiretroviral drugs accounted for 30% (198 Canadian dollars PPPM) of the total cost in 1995/96 increasing to 69% (775 Canadian dollars PPPM) in 2000/01. Inpatient, outpatient and home care costs decreased in both percentage and cost PPPM between 1995/96 and 2000/01 from 26% to 10%, 27% to 14% and 8% to 3% respectively.
  
  
  CONCLUSIONS
  The cost of providing medical care to HIV-positive patients continues to increase, although the burden of costs is distributed differently from before the introduction of HAART, with the costs of drug therapy offsetting the costs of inpatient care and home care. Careful consideration of all aspects of direct costing data is needed when any health economic policy issues are examined.
authors.affiliation: Southern Alberta HIV/AIDS Clinic and the Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB. Harmut.Krentz@CalgaryHealthRegion.ca
authors.forename: Hartmut B
authors.initials: HB
authors.lastname: Krentz
authors.forename: M Christopher
authors.initials: MC
authors.lastname: Auld
authors.forename: M John
authors.initials: MJ
authors.lastname: Gill
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000191:economics* / Q000628:therapy; D000328:Adult; D000416:Alberta; D000553:Ambulatory Care / Q000191:economics; D019380:Anti-HIV Agents / Q000191:economics; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics*; D017048:Health Care Costs; D006699:Home Care Services / Q000191:economics; D017721:Hospital Costs; D006801:Humans; D008297:Male; D019472:Universal Health Insurance / Q000191:economics
chemical_list: D019380:Anti-HIV Agents